Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722728 | 0.89 | PRMT5 (0.40) | DAOHCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL29327043 | 0.89 | PRMT5 (0.40) | DAOHCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL56939 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL17107724 | 0.84 | HCAR2 (0.48) | DAOHCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL3551909 | 0.82 | HCAR2 (0.49) | DAOHCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL1269829 | 0.82 | HCAR2 (0.53) | DAOHCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL29327040 | 0.81 | HCAR2 (0.47) | DAOHCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL16247075 | 0.81 | HCAR2 (0.47) | DAOHCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL14722873 | 0.81 | MKNK1 (0.35) | HCAR2MKNK1MKNK2HCAR3 | |
| SCHEMBL31080297 | 0.80 | HCAR2 (0.37) | HCAR2MKNK1MKNK2HCAR3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| CN-101501030-A | Pyrimidine derivatives useful in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | DAO 4313/4885HCAR2 647/4885MKNK1 32/4885 |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | DAO 4077/4885HCAR2 483/4885MKNK1 28/4885 |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | DAO 3414/4885HCAR2 2636/4885MKNK1 762/4885 |
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | DAO 824/4885HCAR2 3952/4885MKNK1 2009/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | DAO 4313/4885HCAR2 647/4885MKNK1 32/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | DAO 4313/4885HCAR2 647/4885MKNK1 32/4885 |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | DAO 3766/4885HCAR2 495/4885MKNK1 224/4885 |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | DAO 4304/4885HCAR2 492/4885MKNK1 32/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | DAO 4313/4885HCAR2 647/4885MKNK1 32/4885 |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | DAO 4304/4885HCAR2 492/4885MKNK1 32/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | DAO 4285/4885HCAR2 1017/4885MKNK1 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.